NASDAQ:EYEG - Eyegate Pharmaceuticals Stock Price, Forecast & News

Eyegate Pharmaceuticals' stock was trading at $5.03 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, EYEG stock has decreased by 10.7% and is now trading at $4.49. View which stocks have been mosted impacted by Coronavirus.

Eyegate Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, May 13th 2020. View our earnings forecast for Eyegate Pharmaceuticals.

Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) posted its quarterly earnings data on Tuesday, November, 13th. The specialty pharmaceutical company reported ($0.07) earnings per share for the quarter, topping analysts' consensus estimates of ($0.08) by $0.01. The specialty pharmaceutical company had revenue of $0.32 million for the quarter, compared to analyst estimates of $0.19 million. View Eyegate Pharmaceuticals' earnings history.

Media stories about EYEG stock have trended somewhat positive recently, according to InfoTrie Sentiment. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Eyegate Pharmaceuticals earned a media sentiment score of 1.2 on InfoTrie's scale. They also gave media stories about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news aboutEyegate Pharmaceuticals.

Eyegate Pharmaceuticals saw a decline in short interest in March. As of March 13th, there was short interest totaling 16,900 shares, a decline of 56.0% from the February 27th total of 38,400 shares. Based on an average daily trading volume, of 26,000 shares, the days-to-cover ratio is presently 0.7 days. Currently, 0.4% of the company's stock are sold short. View Eyegate Pharmaceuticals' Current Options Chain.

Some companies that are related to Eyegate Pharmaceuticals include Clearside Biomedical (CLSD), Immunic (IMUX), Aptorum Group (APM), Monopar Therapeutics (MNPR), Aravive (ARAV), Adamas Pharmaceuticals (ADMS), SUMMIT THERAPEU/S (SMMT), Menlo Therapeutics (MNLO), SCYNEXIS (SCYX), Galmed Pharmaceuticals (GLMD), Vaccinex (VCNX), Catabasis Pharmaceuticals (CATB), CV Sciences (CVSI), Cassava Sciences (SAVA) and AVEO Pharmaceuticals (AVEO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Eyegate Pharmaceuticals investors own include Bausch Health Companies (BHC), MannKind (MNKD), Sorrento Therapeutics (SRNE), Novavax (NVAX), Progenics Pharmaceuticals (PGNX), Anavex Life Sciences (AVXL), Arca Biopharma (ABIO), Inovio Pharmaceuticals (INO), Nektar Therapeutics (NKTR) and T2 Biosystems (TTOO).

(EYEG) raised $5 million in an IPO on Friday, February 13th 2015. The company issued 800,000 shares at a price of $6.00 per share. Aegis Capital Corp and Chardan Capital Markets served as the underwriters for the IPO.

Eyegate Pharmaceuticals trades on the NASDAQ under the ticker symbol "EYEG."

Eyegate Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Geode Capital Management LLC (0.83%), Renaissance Technologies LLC (0.81%) and Virtu Financial LLC (0.32%). Company insiders that own Eyegate Pharmaceuticals stock include Armistice Capital Master Fund, Brenda Mann, Morton Goldberg, Sarah Romano and Stephen From. View institutional ownership trends for Eyegate Pharmaceuticals.

EYEG stock was purchased by a variety of institutional investors in the last quarter, including Geode Capital Management LLC, Renaissance Technologies LLC, and Virtu Financial LLC. View insider buying and selling activity for Eyegate Pharmaceuticals.

Shares of EYEG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of EYEG stock can currently be purchased for approximately $4.49.

Eyegate Pharmaceuticals has a market capitalization of $20.79 million and generates $2.69 million in revenue each year. The specialty pharmaceutical company earns $-7,100,000.00 in net income (profit) each year or ($2.23) on an earnings per share basis. Eyegate Pharmaceuticals employs 11 workers across the globe. View additional information about Eyegate Pharmaceuticals.

The official website for Eyegate Pharmaceuticals is http://www.eyegatepharma.com/.

Eyegate Pharmaceuticals' mailing address is 271 WAVERLEY OAKS ROAD SUITE 108, WALTHAM MA, 02452. The specialty pharmaceutical company can be reached via phone at 781-788-8869.